Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1ALN-62643----2件: 62, 109
2ALN-CC5----4件: 11, 62, 66, 109
3ALXN1210----7件: 2, 11, 13, 50, 62, 66, 109
4Anti-C5 antibody----4件: 11, 14, 62, 109
5C5 inh MAb, SKY59, RO/CH7092230----2件: 62, 109
6CCX168----5件: 43, 44, 66, 109, 222
7Cemdisiran1件: Cemdisiran---4件: 11, 62, 66, 109
8COVERSIN1件: Nomacopan1件: D11473 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 62, 109
9CROVALIMAB1件: Crovalimab1件: D11696 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 62, 109
10ECULIZUMAB1件: Eculizumab1件: D03940 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 11, 13, 14, 61, 62, 109, 222
11Fc- and CDR-modified humanised monoclonal antibody against C5----3件: 11, 62, 109
12IgG2/4?----1件: 109
13Iptacopan1件: Iptacopan1件: D12251 1件: CFB 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬5件: 61, 62, 66, 109, 222
14LNP023----5件: 61, 62, 66, 109, 222
15MASP-2 antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬3件: 64, 66, 109
16NM8074----2件: 62, 109
17OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬1件: 109
18OMS721----3件: 64, 66, 109
19OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 64, 109
20OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 64, 109
21OMS721 Drug Product 185 mg/mL----1件: 109
22RAVULIZUMAB1件: Ravulizumab1件: D11054 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 2, 11, 13, 50, 62, 66, 109
23RO7112689/F03-01----2件: 62, 109
24RO7112689/F03-10----2件: 62, 109
25RVA576----3件: 62, 109, 162
26RVA576 (COVERSIN)1件: Nomacopan1件: D11473 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 62, 109
27Solaris----2件: 62, 109
28SOLIRIS1件: Eculizumab1件: D03940 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 11, 13, 14, 61, 62, 109, 222
29SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)1件: Eculizumab1件: D03940 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬3件: 13, 62, 109
30SOLIRIS 300 mg concentrado para solución para perfusión1件: Eculizumab1件: D03940 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 109
31 LNP023 HYDROCHLORIDE SALT----5件: 61, 62, 66, 109, 222